Back to News
Market Impact: 0.15
Barclays Initiates Coverage of Ligand Pharmaceuticals Incorporated - Equity Right at Overweight
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Barclays initiated coverage of Ligand Pharmaceuticals Incorporated - Equity Right (OTCPK:LGNYZ) on September 25, 2026, with an Overweight rating. The positive analyst initiation may support investor interest in the biotech-linked security, though the article provides no price target, financial estimates, or operating update.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
BCS0.10
LGND0.45
More News
- Humana surges: Barclays bets big on Medicare star ratings rebound
- Top Wall Street Forecasters Revamp Levi Strauss Expectations Ahead Of Q3 Earnings
- PepsiCo Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
- Shares of Akamai surge after deal with Anthropic. What Wall Street is saying
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- Why Microsoft Stock Is Up Today